Trevi Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Trevi Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q4 2024.
  • Trevi Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$11.4M, a 46% decline year-over-year.
  • Trevi Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$47.9M, a 64.8% decline year-over-year.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$47.9M, a 64.8% decline from 2023.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.1M, a 0.3% increase from 2022.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$29.2M, a 14.1% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.